Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) dropped 1.4% during mid-day trading on Tuesday . The stock traded as low as $369.59 and last traded at $370.51, with a volume of 339,886 shares trading hands. The stock had previously closed at $375.74.

A number of research firms have recently weighed in on REGN. Robert W. Baird reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, May 16th. Vetr upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $429.64 price target for the company in a report on Monday, June 13th. Leerink Swann reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Saturday, April 9th. Sanford C. Bernstein reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, June 30th. Finally, Chardan Capital reiterated a “sell” rating and set a $325.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, March 25th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $508.32.

The firm’s 50 day moving average price is $371.20 and its 200-day moving average price is $400.83. The firm has a market cap of $37.81 billion and a PE ratio of 57.48.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $2.57 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.58 by $0.01. During the same quarter last year, the business posted $2.88 EPS. The company earned $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. The business’s quarterly revenue was up 38.0% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals Inc. will post $10.86 EPS for the current year.

In related news, major shareholder Sanofi purchased 64,731 shares of the company’s stock in a transaction dated Tuesday, June 14th. The shares were acquired at an average cost of $363.86 per share, for a total transaction of $23,553,021.66. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Plew Daniel P. Van sold 4,413 shares of the stock in a transaction that occurred on Wednesday, May 18th. The stock was sold at an average price of $385.77, for a total value of $1,702,403.01. Following the sale, the executive vice president now owns 11,381 shares in the company, valued at $4,390,448.37. The disclosure for this sale can be found here.

Other hedge funds recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 4,557,687 shares of the biopharmaceutical company’s stock worth $2,474,232,000 after buying an additional 131,565 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.9% in the fourth quarter. Jennison Associates LLC now owns 2,016,027 shares of the biopharmaceutical company’s stock worth $1,094,441,000 after buying an additional 93,894 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Regeneron Pharmaceuticals by 5.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 136,447 shares of the biopharmaceutical company’s stock worth $74,078,000 after buying an additional 7,316 shares during the last quarter. Mizuho Trust & Banking Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 0.9% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 114,567 shares of the biopharmaceutical company’s stock worth $62,804,000 after buying an additional 1,016 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Principal Financial Group Inc. now owns 106,583 shares of the biopharmaceutical company’s stock worth $57,861,000 after buying an additional 2,198 shares during the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.